Welcome to our dedicated page for AstraZeneca news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca stock.
AstraZeneca PLC develops and commercializes prescription medicines across oncology, rare diseases, and BioPharmaceuticals, including cardiovascular, renal and metabolism, respiratory, and immunology. News about AZN commonly covers clinical-trial results, FDA and advisory-committee actions, product approvals, and updates to marketed medicines such as TRUQAP, BREZTRI, SAPHNELO, IMFINZI, IMJUDO, and ULTOMIRIS.
Company updates also address quarterly revenue and earnings trends, alliance and collaboration revenue, licensing transactions for pipeline assets, and governance changes. Recurring development themes include targeted oncology, COPD, asthma, systemic lupus erythematosus, liver cancer, prostate cancer, and rare or immune-mediated diseases.
SOPHiA GENETICS (Nasdaq: SOPH) has expanded its collaboration with AstraZeneca to enhance breast and prostate cancer detection through advanced AI technology. The partnership focuses on developing an optimized next-generation sequencing (NGS) solution that employs AI algorithms to detect genetic mutations in the PIK3CA/AKT1/PTEN pathway.
The companies have already developed a prototype demonstrating improved sensitivity in mutation detection. SOPHiA GENETICS will implement a Privileged Access Program for selected clinical laboratories, with broader commercial availability expected in 2026. The program includes a multi-center real-world evidence study to validate the technology's effectiveness in clinical settings.
AstraZeneca (NYSE:AZN) announced that the FDA has approved an updated US prescribing information for AIRSUPRA® to include data from the BATURA Phase IIIb trial in mild asthma patients. The study demonstrated that AIRSUPRA significantly reduced the risk of severe exacerbations by 46% compared to albuterol in adult patients with mild asthma.
The BATURA trial results, published in the New England Journal of Medicine, showed positive outcomes including reduced annualized severe exacerbation rates and systemic steroid dose. AIRSUPRA maintains its position as the first and only FDA-approved anti-inflammatory rescue medication for as-needed treatment of bronchoconstriction and exacerbation risk reduction in asthma patients aged 18 and older.
AstraZeneca (NYSE:AZN) announced positive interim results from its Phase III TULIP-SC trial evaluating SAPHNELO's subcutaneous administration for systemic lupus erythematosus (SLE) treatment. The trial demonstrated statistically significant and clinically meaningful reduction in disease activity compared to placebo, with a safety profile consistent with its intravenous formulation.
The study involved 367 participants with moderately to severely active, autoantibody-positive SLE, randomized 1:1 to receive either 120mg subcutaneous SAPHNELO or placebo weekly. The interim analysis was conducted when the first 220 participants reached week 52. This new administration method could potentially expand access to SAPHNELO, which is currently approved in over 70 countries and has treated more than 38,000 patients globally.
AstraZeneca (NASDAQ:AZN) announced that the European Medicines Agency (EMA) has validated their Type II Variation application for ENHERTU® for treating adult patients with HER2 positive metastatic solid tumors. The application is supported by data from three phase 2 trials: DESTINY-PanTumor02, DESTINY-CRC02, and DESTINY-Lung01.
If approved, ENHERTU would become the first HER2 directed medicine and antibody drug conjugate to receive a tumor agnostic indication in the EU. The treatment targets patients who have received prior treatment and have no satisfactory alternative treatment options.
AstraZeneca (NYSE:AZN) announced final overall survival (OS) results from the FLAURA2 Phase III trial showing TAGRISSO® (osimertinib) plus chemotherapy achieved a median OS of 47.5 months compared to 37.6 months with TAGRISSO alone in first-line EGFRm advanced lung cancer treatment.
The combination therapy demonstrated a 23% reduction in death risk (HR=0.77; p=0.0202) with 63.1% of patients alive at three years versus 50.9% for monotherapy. The survival benefit was consistent across all subgroups, setting a new survival benchmark in EGFR-mutated lung cancer treatment.
While Grade 3+ adverse events were higher with combination therapy (70% vs 34%), the safety profile remained manageable with low discontinuation rates (12% vs 7%).
AstraZeneca (NYSE:AZN) announced positive Phase III trial results for baxdrostat in treating hard-to-control hypertension. The trial met its primary and all secondary endpoints, with the 2mg dose achieving a 15.7 mmHg reduction in systolic blood pressure (9.8 mmHg placebo-adjusted, p<0.001) at 12 weeks.
The drug demonstrated consistent efficacy across both uncontrolled and treatment-resistant subgroups, with the 1mg dose showing an 8.7 mmHg placebo-adjusted reduction. Baxdrostat was generally well-tolerated with low rates of hyperkalemia (1.1%) and mostly mild adverse events.
As a potential first-in-class aldosterone synthase inhibitor, baxdrostat is currently being investigated in clinical trials involving over 20,000 patients globally for various indications including hypertension, primary aldosteronism, chronic kidney disease, and heart failure prevention.
AstraZeneca (NYSE:AZN) has launched FluMist Home, making history as the first FDA-approved influenza vaccine available for self- or caregiver administration at home. The nasal spray vaccine will be available for the 2025-26 flu season in 34 states, covering 80% of eligible populations.
The service allows eligible individuals aged 2-49 to order FLUMIST online after completing a medical screening questionnaire. The vaccine will be delivered in temperature-controlled packaging with clear administration instructions. This initiative comes after the severe 2024-2025 flu season, which resulted in 610,000 hospitalizations and 27,000 deaths.
FluMist Home represents a significant advancement in preventive healthcare delivery, offering a needle-free option that can be administered without visiting medical facilities.
AstraZeneca (NYSE:AZN) and Viseven have been awarded the prestigious 2025 ACE Awards by the Healthcare Businesswomen's Association (HBA) for their innovative workforce development programs. AstraZeneca's Young Health Programme (YHP) received the 2025 ACE Award, while Viseven's Expert Communities and Unicorns Recognition Program was honored with the 2025 ACE Aspire Award.
The ACE Awards recognize programs that demonstrate excellence in advancing, committing to, and engaging healthcare workforce development. These awards specifically highlight initiatives that prioritize people-first approaches, demonstrate global scalability, and deliver measurable business and social outcomes in the healthcare sector.
SOPHiA GENETICS (Nasdaq: SOPH) has expanded its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN) in a multi-year collaboration focused on breast cancer treatment optimization. The partnership will utilize SOPHiA GENETICS's multimodal AI Factories to analyze genomics, imaging, and clinical data to generate evidence on therapy efficacy and develop AI-powered predictive models.
The collaboration aims to generate real-world evidence in Europe and North America, leveraging one of healthcare's most diverse multimodal datasets to enhance clinical decision-making and treatment outcomes. The partnership highlights SOPHiA GENETICS's capabilities in managing complex healthcare data environments through secure, compliant, and scalable real-world AI applications.
AstraZeneca (NYSE:AZN) reported strong H1 2025 financial results with Total Revenue up 11% to $28,045 million at constant exchange rates. The company delivered Core EPS of $4.66, a 17% increase, driven by robust performance across all major geographic regions.
Key achievements include 12 positive Phase III readouts and 19 regulatory approvals in major regions. The company announced a landmark $50 billion investment in US operations, including its largest-ever manufacturing facility in Virginia. AstraZeneca increased its interim dividend by 3% to $1.03 and maintained its FY 2025 guidance of high single-digit revenue growth and low double-digit Core EPS growth.